Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
Biocon has reported consolidated financial results for the period ended December 31, 2021
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
However, these won’t be available at the nearest chemist store soon
Unlike most data analysis services, Dolomite Bio will accept sample sizes ranging from as little as one sample, to as many as the research project requires
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Subscribe To Our Newsletter & Stay Updated
